Investigators conducted a retrospective analysis at 19 trial sites where patients received at least one dose of the KEYNOTE-522 regimen for triple-negative breast cancer.
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Thursday positive results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial investigating ...
KEYTRUDA® (pembrolizumab) is the first and only immunotherapy-based regimen to show a statistically significant improvement in OS as pre-operative (neoadjuvant) treatment with chemotherapy and then as ...
At the virtual San Antonio Breast Cancer Symposium (SABCS), researchers presented findings from two clinical trials -- KEYNOTE 522 and KEYNOTE 355-- showing that the immunotherapy pembrolizumab ...
Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, continued as a single agent after surgery, significantly improved event-free survival in patients with high-risk, early-stage triple-negative ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...
Survival, Toxicity, and Economic Outcomes of Osimertinib Versus Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Epidermal Growth Factor Receptor–Mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results